An interventional study of Accelerated intensity modulated radiation therapy (AIMRT) in Breast Cancer, sponsored by NYU Langone Health. Completed at 1 site in United States. Open to female participants aged 19 Years to 90 Years. Per ClinicalTrials.gov, last updated 2020-08-14.
Sponsored by NYU Langone Health · Not applicable, Interventional, and Treatment
The primary purpose of this study is to determine the feasibility and tolerability of a regimen of accelerated (hypofractionated) Intensity Modulated Radiation Therapy (AIMRT) to the whole breast as part of breast preservation. In addition, the investigators want to prospectively collect blood specimens to: assess TGF-β polymorphisms to identify potential carriers at higher risk for post-treatment fibrosis; generate a blood specimen repository for future studies of other relevant polymorphisms. The study investigators also want to prospectively follow each treated woman yearly to assess long-term radiation sequelae of the current regimen by using the LENT/SOMA scores.
Despite level I evidence of comparable efficacy to that of mastectomy, breast conserving therapy (BCT) remains underutilized in the United States. In 1990, the National Institutes of Health (NIH) Consensus Development Conference concluded that BCT was the appropriate method of treatment for the majority of women with early stage I and II breast cancer. However, this subsequently only translated in a moderate increase in the utilization of BCT, shifting from 34% to 60% for stage I breast cancer and from 19% to 39% for stage II breast cancer.
There appear to be multiple causes for underutilization. The demands of the standard radiation schedule probably play the main role. Generally, post-lumpectomy radiation therapy consists of 4 to 5 weeks of whole breast radiation of a total dose 45 to 50 Gy in 23-25 fractions, usually followed by a boost of 10 to 16 Gy in 5-8 fractions to the tumor bed area. The total length of treatment is 5-7 weeks, commonly six weeks. Practically, women who choose BCT automatically commit to a regimen of approximately six weeks of daily radiation visits (Monday to Friday) to complete the local management of their breast cancer. For many women, concerns about this commitment are likely to influence the choice for mastectomy instead of breast preservation since only 40-60% of women who meet criteria for BCT actually undergo the procedure. In addition to possible biases of the primary health care provider affecting these choices, it is known that distance from RT treatment facilities also plays an important role in women's choice for mastectomy instead of BCT. Unfortunately, 15-30% of patients who have actually selected BCT, in particularly older patients and those with 2 or more co-morbid conditions, do not receive postoperative RT. These facts warrant a critical assessment of standard radiation therapy in this clinical setting.
The actual standard approach to post-segmental mastectomy adjuvant radiation at our institution consists of surgical excision followed by 6 weeks of breast irradiation for a total of 30 fractions of 2 Gy each, 23 (46 Gy) to the whole breast while 7 to the original tumor bed (14 Gy). Instead, the women in this study will only receive 15 larger radiation fractions (2.7 Gy) to the entire breast with a concomitant boost to the tumor bed (2.7 Gy + .5 Gy, total 3.2 Gy per fraction). All women will be treated prone to best apply IMRT techniques while avoiding the rest of the body.
Treatment with fewer fractions over a shorter duration of time offers several advantages, provided it is as effective as the conventional treatment regimens and without added morbidity. The potential advantages include: 1) less time away from homes, families and jobs; 2) less cost associated with travel and time away from work; 3) ease the demand on radiation treatment resources and produce savings to the health-care system. Moreover, treatment prone assures that only minimal dose of radiation is delivered to the lung, heart and to the controlateral breast.
Patients will have completed all breast surgical procedures prior to accrual into this protocol in order to establish eligibility criteria. All patients will then be treated prone with 2.7 Gy/fraction delivered in 15 fractions over a 3-week period for a total dose of 40.5 Gy.
All patients will be followed 1, 3, 6, 12 months after treatment course, then yearly thereafter.
NYU Langone Health is the lead sponsor of 1,391 studies on the registry; 254 are open to participants now.
Of its 227 completed or terminated interventional studies of FDA-regulated products, 191 (84%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields. A concurrent boost to the original tumor bed of 0.50 Gy will be delivered.
Radiation: Accelerated intensity modulated radiation therapy (AIMRT)
Number of Participants With Local Recurrence in Breast
Defined by the discovery of invasive disease or DCIS in the same region of the breast after segmental mastectomy and radiation, by clinical or radiographic means.
Time frame: 5 years
Number of Participants With Regional Recurrence
Defined by the discovery of invasive disease or DCIS regional recurrence in the lymph node after segmental mastectomy and radiation, by clinical or radiographic means.
Time frame: 5 years
Number of Participants With Contralateral Breast Cancer
Defined by the discovery of contra-lateral breast cancer after segmental mastectomy and radiation, by clinical or radio-graphic means.
Time frame: 5 years
Number of Participants With Distant Metastases
number of participants found to have distant metastases after segmental mastectomy and radiation, by clinical or radiographic means
Time frame: 5 years
Number of Participants With an Outcome of Death
Overall 5-Year cumulative rate of death based on Kaplan-Meier Analysis
Time frame: 5 years
Maximum Grade Late Radiation Toxicity
Measure of treatment related late toxicities at or more than 6 months after completion of radiation therapy.
Time frame: 5 years
Patient Self-assessment of the Cosmetic Results
Time frame: 5 years
Survival
Time frame: 5 years
| Milestone | Accelerated Intensity Modulated Radiation Therapy (AIMRT) |
|---|---|
| Started | 314 |
| Completed | 314 |
| Not completed | 0 |
Defined by the discovery of invasive disease or DCIS in the same region of the breast after segmental mastectomy and radiation, by clinical or radiographic means.
| Participants | Accelerated Intensity Modulated Radiation Therapy (AIMRT) |
|---|---|
| Number of Participants With Local Recurrence in Breast | 6 |
Defined by the discovery of invasive disease or DCIS regional recurrence in the lymph node after segmental mastectomy and radiation, by clinical or radiographic means.
| Participants | Accelerated Intensity Modulated Radiation Therapy (AIMRT) |
|---|---|
| Number of Participants With Regional Recurrence | 4 |
Defined by the discovery of contra-lateral breast cancer after segmental mastectomy and radiation, by clinical or radio-graphic means.
| Participants | Accelerated Intensity Modulated Radiation Therapy (AIMRT) |
|---|---|
| Number of Participants With Contralateral Breast Cancer | 2 |
number of participants found to have distant metastases after segmental mastectomy and radiation, by clinical or radiographic means
| Participants | Accelerated Intensity Modulated Radiation Therapy (AIMRT) |
|---|---|
| Number of Participants With Distant Metastases | 8 |
Overall 5-Year cumulative rate of death based on Kaplan-Meier Analysis
| Participants | Accelerated Intensity Modulated Radiation Therapy (AIMRT) |
|---|---|
| Number of Participants With an Outcome of Death | 17 |
Measure of treatment related late toxicities at or more than 6 months after completion of radiation therapy.
| Participants | Accelerated Intensity Modulated Radiation Therapy (AIMRT) |
|---|---|
| Pigmentation Change — Grade 1 | 62 |
| Pigmentation Change — Grade 2 | 2 |
| Pigmentation Change — Grade 3 | 0 |
| Breast Fibrosis — Grade 1 | 59 |
| Breast Fibrosis — Grade 2 | 13 |
| Breast Fibrosis — Grade 3 | 1 |
| Breast Retraction — Grade 1 | 46 |
| Breast Retraction — Grade 2 | 17 |
| Breast Retraction — Grade 3 | 2 |
| Breast Telangiectasia — Grade 1 | 47 |
| Breast Telangiectasia — Grade 2 | 19 |
| Breast Telangiectasia — Grade 3 | 4 |
| Breast Edema — Grade 1 | 10 |
| Breast Edema — Grade 2 | 0 |
| Breast Edema — Grade 3 | 1 |
| Breast Pain — Grade 1 | 28 |
| Breast Pain — Grade 2 | 1 |
| Breast Pain — Grade 3 | 0 |
| Arm Lymphadema — Grade 1 | 1 |
| Arm Lymphadema — Grade 2 | 0 |
| Arm Lymphadema — Grade 3 | 1 |
| Participants | Accelerated Intensity Modulated Radiation Therapy (AIMRT) |
|---|---|
| Excellent/Good | 251 |
| Fair | 56 |
| Poor | 7 |
| percentage of Patients | Accelerated Intensity Modulated Radiation Therapy (AIMRT) |
|---|---|
| Survival | 94.6 |
Collected over 5 Years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Accelerated Intensity Modulated Radiation Therapy (AIMRT) | 17/314 (5.4%) | 0/314 (0%) | 96/314 (30.6%) |
| Event | Accelerated Intensity Modulated Radiation Therapy (AIMRT) |
|---|---|
| FatigueGeneral disorders | 46/314 |
| Hot flashesEndocrine disorders | 42/314 |
| ARTHRITISMusculoskeletal and connective tissue disorders | 4/314 |
| PericarditisCardiac disorders | 2/314 |
| HypertensionCardiac disorders | 1/314 |
| Hemolitic autoimmune anemiaBlood and lymphatic system disorders | 1/314 |
| DepressionNervous system disorders | 1/314 |
| PAIN lower extremitiesNervous system disorders | 1/314 |
| Hair lossSkin and subcutaneous tissue disorders | 1/314 |
| Bone PainMusculoskeletal and connective tissue disorders | 1/314 |
| Age, Categorical(Participants) | Accelerated Intensity Modulated Radiation Therapy (AIMRT) |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 188 |
| >=65 years | 126 |
| Sex: Female, Male(Participants) | Accelerated Intensity Modulated Radiation Therapy (AIMRT) |
|---|---|
| Female | 314 |
| Male | 0 |
| Race/Ethnicity, Customized(Participants) | Accelerated Intensity Modulated Radiation Therapy (AIMRT) |
|---|---|
| White | 220 |
| Black | 60 |
| Asian | 22 |
| Hispanic | 12 |
| Region of Enrollment(Participants) | Accelerated Intensity Modulated Radiation Therapy (AIMRT) |
|---|---|
| United States | 314 |
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
NYU Langone Health